TITLE

Abstral

PUB. DATE
February 2011
SOURCE
Pharmaceutical Representative;Feb2011, Vol. 41 Issue 2, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article presents the approval of abstral (fentanyl) transmucosal tablets from ProStraken designed to manage breakthrough pain for adult cancer patients.
ACCESSION #
58103693

 

Related Articles

  • Bonefos.  // Royal Society of Medicine: Medicines;2002, p118 

    The article presents information on Bonefos, a, proprietary, prescription-only preparation of sodium clodronate. It is used to treat high calcium levels associated with malignant tumors and bone lesions. It is available in a number of forms (one called Bonefos Concentrate), as tablets, capsules...

  • Abiraterone.  // AHFS Consumer Medication Information;Oct2017, p1 

    Abiraterone is used in combination with another medication (prednisone) to treat prostate cancer that has spread to other parts of the body in men who have not been helped by other treatments including docetaxel (Docefrez, Taxotere). Abiraterone is in a class of medications called androgen...

  • ONCOLOGY.  // MPR - Urologists' Edition;Spring/Summer2012, Vol. 9 Issue 1, p51 

    The article offers brief information on several oncologic drugs including Zytiga tablets from Janssen Biotech Inc., Casodex tablets from AstraZeneca PLC and Lupron Depot suspension from Abbott Laboratories Inc.

  • Comparison of pharmacokinetics and safety profiles of two capecitabine tablet formulations in patients with colon, colorectal or breast cancer. Chachad, Siddharth; Purandare, Shrinivas; Malhotra, Geena; Naidu, Raghu // Cancer Chemotherapy & Pharmacology;Feb2013, Vol. 71 Issue 2, p287 

    Purpose: The objective of this study was to compare the pharmacokinetics and safety of two tablet formulations containing 500 mg of capecitabine (CAS number 154361-50-9) in patients with colon, colorectal or breast cancer. Methods: The study was a multicentric, open label, randomized,...

  • Preparation and Evaluation of Immediate Release tablet of Metoclopramide HCl using Simplex Centroid Mixture Design. Rao, Monica R. P.; Gogad, Vishal K.; Sonar, Girish S.; Vanshiv, Swapnila D.; Badhe, Amruta S. // International Journal of PharmTech Research;Apr2010, Vol. 2 Issue 2, p1105 

    Metoclopramide HCl is mainly used as an anti-emetic agent in the cancer chemotherapy. It also stimulates the upper GI tract and is used in the management of some forms of nausea, vomiting and pain associated with migraine as well as in gastric stasis where quick onset of action is required....

  • NEW INDICATIONS.  // Drug Topics;8/7/2006, Vol. 150 Issue 15, p44 

    The article presents several approvals for various new drug indications in the U.S. GlaxoSmithKline Corp., leading research-based pharmaceutical firm has received approval for its two new drug indications including Avandamet tablets contain two ingredients, rosiglitazone maleate and metformin...

  • Formulation and In Vitro, In Vivo Evaluation of Effervescent Floating Sustained-Release Imatinib Mesylate Tablet. Kadivar, Ali; Kamalidehghan, Behnam; Javar, Hamid Akbari; Davoudi, Ehsan Taghizadeh; Zaharuddin, Nurul Dhania; Sabeti, Bahareh; Chung, Lip Yong; Noordin, Mohamed Ibrahim // PLoS ONE;Jun2015, Vol. 10 Issue 6, p1 

    Introduction: Imatinib mesylate is an antineoplastic agent which has high absorption in the upper part of the gastrointestinal tract (GIT). Conventional imatinib mesylate (Gleevec) tablets produce rapid and relatively high peak blood levels and requires frequent administration to keep the...

  • Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Bennett, Antonia V.; Dueck, Amylou C.; Mitchell, Sandra A.; Mendoza, Tito R.; Reeve, Bryce B.; Atkinson, Thomas M.; Castro, Kathleen M.; Denicoff, Andrea; Rogak, Lauren J.; Harness, Jay K.; Bearden, James D.; Bryant, Donna; Siegel, Robert D.; Schrag, Deborah; Basch, Ethan; National Cancer Institute PRO-CTCAE Study Group // Health & Quality of Life Outcomes;2/19/2016, Vol. 14, p1 

    Background: PRO-CTCAE is a library of items that measure cancer treatment-related symptomatic adverse events (NCI Contracts: HHSN261201000043C and HHSN 261201000063C). The objective of this study is to examine the equivalence and acceptability of the three data collection modes...

  • Drug Combination Targets Brain Cancer. Gallant, Julie // San Diego Business Journal;5/14/2012, Vol. 33 Issue 20, p1 

    The article focuses on the clinical trials for the treatment of recurrent brain cancer developed by Tocagen Inc. It says that the trials at University of California (UC) San Diego Moores Cancer Center investigates the use of Toca 511, a retroviral replicating vector, and Toca FC tablets with...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics